Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Revvity Inc. (NYSE:RVTY). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Revvity stock on September 3rd.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
- Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
- Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
- Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
- Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
- Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
- Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
- Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
- Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
- Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.
Revvity Trading Down 1.8%
Revvity stock opened at $152.28 on Thursday. The stock has a market cap of $16.99 billion, a P/E ratio of 28.99, a PEG ratio of 2.82 and a beta of 1.06. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. Revvity Inc. has a 1 year low of $81.22 and a 1 year high of $166.25. The firm’s 50 day moving average price is $134.92 and its 200-day moving average price is $112.65.
Revvity Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a dividend of $0.07 per share. The ex-dividend date is Friday, October 23rd. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. Revvity’s dividend payout ratio (DPR) is presently 13.33%.
Analyst Ratings Changes
RVTY has been the subject of several research reports. William Blair initiated coverage on shares of Revvity in a report on Monday, October 5th. They set an “outperform” rating for the company. Royal Bank Of Canada initiated coverage on Revvity in a report on Tuesday, September 1st. They issued a “sector perform” rating and a $135.00 target price on the stock. TD Cowen lifted their target price on Revvity from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday. Sanford C. Bernstein began coverage on Revvity in a research report on Friday, June 26th. They issued a “market perform” rating and a $115.00 target price on the stock. Finally, Wall Street Zen downgraded Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Five analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. According to MarketBeat, Revvity currently has a consensus rating of “Hold” and an average target price of $124.43.
Get Our Latest Research Report on RVTY
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of RVTY. Jupiter Topco LLC bought a new stake in Revvity in the second quarter worth $961,017,000. BlackRock Inc. purchased a new stake in Revvity during the second quarter valued at $852,070,000. Wellington Management Group LLP raised its stake in Revvity by 10,653.8% during the second quarter. Wellington Management Group LLP now owns 865,575 shares of the company’s stock valued at $96,304,000 after purchasing an additional 857,526 shares in the last quarter. Primecap Management Co. CA bought a new position in Revvity during the second quarter valued at $94,921,000. Finally, Bank of America Corp DE bought a new position in Revvity during the second quarter valued at $87,116,000. 86.65% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Revvity news, insider Tajinder Vohra sold 7,330 shares of Revvity stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the transaction, the insider directly owned 6,635 shares of the company’s stock, valued at $934,738.80. This trade represents a 52.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Maxwell Krakowiak sold 1,631 shares of the business’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the sale, the insider owned 14,781 shares in the company, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 9,130 shares of company stock valued at $1,290,745 over the last three months. Corporate insiders own 0.85% of the company’s stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
Revvity Company Profile
Revvity, Inc (NYSE:RVTY) is a life sciences and diagnostics company that provides technologies, products and services used in biological research, drug discovery, clinical testing and healthcare. The company serves pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, clinical laboratories and other healthcare organizations.
Its portfolio includes instruments, reagents, consumables, software and related services for areas such as genomics, proteomics, cellular analysis, imaging and multiplex testing.
Recommended Stories
- Five stocks we like better than Revvity
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
